Influenza drug oseltamivir has made vast amounts of pounds for Roche, but why won’t the organization give patients and physicians usage of the total data that are clinical? Included in the BMJ’s open information campaign, we this week introduce a brand new website committed to your cause. David Payne reports
This week the BMJ, included in its ongoing data that are open, has launched a separate website aimed at persuading Roche to provide physicians and clients usage of the total information on oseltamivir (Tamiflu).
The brand new website, shows e-mails and letters dating returning to September 2009, when researcher Tom Jefferson first asked the organization for the unpublished dataset utilized in a Roche supported analysis, posted in 2003.1
Jefferson required the info by the month that is following upgrade the Cochrane Collaboration’s review on neuraminidase inhibitors in healthy grownups. To start with the ongoing business asked him to signal a privacy agreement guaranteeing he will never publish the information in complete.2
Then it declined to provide it regarding the grounds it was in fact approached by an separate expert influenza team undertaking the same meta-analysis and wished to avoid a conflict. Roche included that its study reports had already been distributed to the authorities that are regulatory.
Jefferson told the ongoing business within an email: “I recognise that more and more people than me have an interest in reviewing the studies of interventions for influenza at this time.
“But I don’t realize why this should result in exclusivity, or why you would think that there is a conflict between our intends to upgrade our Cochrane review and also the plans for the other research groups you mention.”
Jefferson’s October deadline passed. 8 weeks later on the Cochrane review, published within the BMJ,3 stated that because eight regarding the 10 randomised trials that are controlled which effectiveness claims had been based had been never published, the data could not be relied on. ...